Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early tripl...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Comment: Pembro plus chemo in neoadjuvant and adjuvant treatment for early triple-negative breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
29 Sep 2019
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
KEYNOTE-522: Immunotherapy and chemo for early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
Comment: Keynote 522 trial
Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy
Comment: Keynote 522 trial ( Prof Guiseppe Curigliano - European Institute of Oncology, Milan, Italy )
29 Sep 2019
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postme...
Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California
CDK4/6 inhibitor ribociclib plus fulvestrant improves overall survival in postmenopausal HR-positive HER2-negative breast cancer ( Prof Dennis Slamon - Ronald Reagan UCLA Medical Center, Los Angeles, California )
29 Sep 2019
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-po...
Prof George Sledge - Stanford Health Care, Stanford, USA
CDK4/6 inhibitor abemaciclib plus fulvestrant improves overall survival in HR-positive/HER2-negative advanced breast cancer ( Prof George Sledge - Stanford Health Care, Stanford, USA )
29 Sep 2019
Comment: CDK4/6 inhibitors in advanced breast cancer
Prof Nadia Harbeck - University of Munich, Munich, Germany
Comment: CDK4/6 inhibitors in advanced breast cancer ( Prof Nadia Harbeck - University of Munich, Munich, Germany )
29 Sep 2019
Immunotherapy added to chemotherapy improves pathological complete response in e...
Prof Peter Schmid - St Bartholomew's Hospital London, London, UK
Immunotherapy added to chemotherapy improves pathological complete response in early triple negative breast cancer ( Prof Peter Schmid - St Bartholomew's Hospital London, London, UK )
29 Sep 2019
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cel...
Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea
ATTRACTION-3: Nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma ( Prof Byoung Chul Cho - Yonsei University, Seoul, South Korea )
29 Sep 2019
Ovarian highlights from ESMO 2019
Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA
Ovarian highlights from ESMO 2019 ( Prof Robert Coleman - MD Anderson Cancer Center, Houston, USA )
28 Sep 2019
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer ...
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation...
Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, ...
Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )
28 Sep 2019
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
28 Sep 2019